Physician profile
William X Coll
NPI 1275526469
$3,692.30
in general payments reported to CMS, 2019-2025
25 companies · $731 in 2025
The $731 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $89.01 · 2022: $391 · 2023: $865 · 2024: $1,061 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,573 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.54 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $964.49 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $456.30 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $452.51 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $357.84 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $225.60 | 2022-2024 | Zeposia |
| Genzyme Corporation | $184.70 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $149.38 | 2023-2025 | Ocaliva |
| Allergan, INC. | $137.36 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $103.46 | 2022-2024 | Rebyota |
| Pfizer INC. | $102.34 | 2019-2024 | |
| Qol Medical, LLC | $101.57 | 2024 | Sucraid |
| Lilly USA, LLC | $59.09 | 2025 | Omvoh |
| Ardelyx, INC. | $57.35 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $54.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $53.73 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $40.14 | 2024-2025 | |
| Braintree Laboratories, INC. | $30.65 | 2023-2024 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $30.58 | 2025 | Zenpep |
| Ucb, INC. | $29.91 | 2019 | |
| Ironwood Pharmaceuticals, INC | $29.77 | 2024 | |
| Amgen INC. | $20.28 | 2022 | |
| Intra-Sana Laboratories | $19.26 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Merck Sharp & Dohme LLC | $17.49 | 2019 | |
| Alfasigma USA, INC. | $14.35 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Coll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.